(Q34200875)

English

Activation of PI3K/AKT and MAPK pathway through a PDGFRβ-dependent feedback loop is involved in rapamycin resistance in hepatocellular carcinoma

scientific article published on 9 March 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Activation of PI3K/AKT and MAPK pathway through a PDGFRβ-dependent feedback loop is involved in rapamycin resistance in hepatocellular carcinoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

1 reference

based on heuristic

inferred from title

author name string

Quan-Lin Li

1

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Fang-Ming Gu

2

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Zheng Wang

3

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Jia-Hao Jiang

4

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Li-Qing Yao

5

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Chang-Jun Tan

6

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Xiao-Yong Huang

7

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Ai-Wu Ke

8

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Zhi Dai

9

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Jia Fan

10

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Jian Zhou

11

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

language of work or name

0 references

publication date

9 March 2012

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

7

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

e33379

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

copyright license

Creative Commons Attribution 4.0 International

9 March 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302853

5 July 2018

Global cancer statistics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302853

5 July 2018

mTOR-dependent regulation of PHLPP expression controls the rapamycin sensitivity in cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302853

5 July 2018

Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: a case report

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302853

5 July 2018

Rapamycin response in tumorigenic and non-tumorigenic hepatic cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302853

5 July 2018

Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302853

5 July 2018

Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302853

5 July 2018

Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302853

5 July 2018

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302853

5 July 2018

PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302853

5 July 2018

Predicted mechanisms of resistance to mTOR inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302853

5 July 2018

Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302853

5 July 2018

How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302853

5 July 2018

Oncogenic derivatives of platelet-derived growth factor receptors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302853

5 July 2018

Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302853

5 July 2018

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302853

5 July 2018

Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302853

5 July 2018

p73 independent of c-Myc represses transcription of platelet-derived growth factor beta-receptor through interaction with NF-Y.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302853

5 July 2018

Sp1 is a key regulator of the PDGF beta-receptor transcription

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302853

5 July 2018

Mechanisms of resistance to rapamycins

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302853

5 July 2018

Mechanism for the transcriptional repression by c-Myc on PDGF beta-receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302853

5 July 2018

Cell signaling by receptor tyrosine kinases

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3302853

5 July 2018

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0033379

21 January 2018

Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0033379

21 January 2018

Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0033379

21 January 2018

Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0033379

21 January 2018

Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0033379

21 January 2018

Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0033379

21 January 2018

Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0033379

21 January 2018

Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0033379

21 January 2018

Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0033379

21 January 2018

Identifiers

10.1371/JOURNAL.PONE.0033379

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

2012PLoSO...733379L

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34200875&oldid=1868083473"